Search in:

Cancer Biology & Therapy Volume 13, 2012 - Issue 10

Submit an article Journal homepage

Free access

1,003

Views

CrossRef citations to date

Altmetric

Research Paper

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer

Kelly M. Quesnelle Department of Pharmacology & Chemical Biology; University of Pittsburgh; Pittsburgh, PA USA; Department of Otolaryngology; University of Pittsburgh; Pittsburgh, PA USA

Sarah E. Wheeler Department of Pathology; University of Pittsburgh; Pittsburgh, PA USA; Department of Otolaryngology; University of Pittsburgh; Pittsburgh, PA USA

Mary K. Ratay Department of Otolaryngology; University of Pittsburgh; Pittsburgh, PA USA

Jennifer R. Grandis Department of Pharmacology & Chemical Biology; University of Pittsburgh; Pittsburgh, PA USA; Department of Pathology; University of Pittsburgh; Pittsburgh, PA USA; Department of Otolaryngology; University of Pittsburgh; Pittsburgh, PA USA; University of Pittsburgh Cancer Institute; University of Pittsburgh; Pittsburgh, PA USACorrespondence[email protected]

Pages 935-945 | Received 20 Mar 2012, Accepted 22 May 2012, Published online: 01 Aug 2012

Cite this article
https://doi.org/10.4161/cbt.20846

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (23)

Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Jöran Melis, Valentin Van den Bossche, Christophe Hermans, Ho Wa Lau, Hilde Lambrechts, Céline Merlin, Cyril Corbet, Marc Peeters, Jan Baptist Vermorken, Jorrit De Waele, Filip Lardon & An Wouters. (2023) Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity. Cancer Drug Resistance 6:4, pages 709-28.
Crossref

Kimberly J. Jasmer, Kevin Muñoz Forti, Lucas T. Woods, Seunghee Cha & Gary A. Weisman. (2022) Therapeutic potential for P2Y2 receptor antagonism. Purinergic Signalling 19:2, pages 401-420.
Crossref

Robert Kleszcz, Marcin Skalski, Violetta Krajka-Kuźniak & Jarosław Paluszczak. (2021) The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells. European Journal of Pharmaceutical Sciences 166, pages 105961.
Crossref

Maria Rivera, Iduna Fichtner, Annika Wulf-Goldenberg, Christine Sers, Johannes Merk, Giannino Patone, Keziban M. Alp, Tamara Kanashova, Philipp Mertins, Jens Hoffmann, Ulrike Stein & Wolfgang Walther. (2021) Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia 23:1, pages 21-35.
Crossref

Maoxiao Yan, Jia Chen, Hua Jiang, Yuqiong Xie, Chunchun Li, Lihong Chen, Beibei Yang & Jiang Cao. (2020) Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3. PLOS ONE 15:8, pages e0237098.
Crossref

Coliat, Ramolu, Jégu, Gaiddon, Jung & Pencreach. (2019) Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC. Cancers 11:10, pages 1607.
Crossref

Rachel A. O'Keefe, Jennifer R. Grandis & Daniel E. Johnson. 2019. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy 1 23 .

Genevieve Stein-O’Brien, Luciane T. Kagohara, Sijia Li, Manjusha Thakar, Ruchira Ranaweera, Hiroyuki Ozawa, Haixia Cheng, Michael Considine, Sandra Schmitz, Alexander V. Favorov, Ludmila V. Danilova, Joseph A. Califano, Evgeny Izumchenko, Daria A. Gaykalova, Christine H. Chung & Elana J. Fertig. (2018) Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance. Genome Medicine 10:1.
Crossref

Shilpa Bhatia, Jaspreet Sharma, Sanjana Bukkapatnam, Ayman Oweida, Shelby Lennon, Andy Phan, Dallin Milner, Nomin Uyanga, Antonio Jimeno, David Raben, Hilary Somerset, Lynn Heasley & Sana D. Karam. (2018) Inhibition of EphB4–Ephrin-B2 Signaling Enhances Response to Cetuximab–Radiation Therapy in Head and Neck Cancers. Clinical Cancer Research 24:18, pages 4539-4550.
Crossref

Chia-Sheng Yen, Cheuk-Sing Choy, Wei-Jan Huang, Shiu-Wen Huang, Pin-Ye Lai, Meng-Chieh Yu, Ching Shiue, Ya-Fen Hsu & Ming-Jen Hsu. (2018) A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade. Frontiers in Pharmacology 9.
Crossref

Ashraf Khalil & Mark J. Jameson. (2017) The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro. Drugs in R&D 17:4, pages 545-555.
Crossref

Heiner Koch, Mathias Wilhelm, Benjamin Ruprecht, Scarlet Beck, Martin Frejno, Susan Klaeger & Bernhard Kuster. (2016) Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells. Journal of Proteome Research 15:12, pages 4490-4504.
Crossref

Yordan Benhamou, Vincent Picco, Hélène Raybaud, Anne Sudaka, Emmanuel Chamorey, Sanja Brolih, Martino Monteverde, Marco Merlano, Cristiana Lo Nigro, Damien Ambrosetti & Gilles Pagès. (2016) Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma. Oncotarget 7:28, pages 44236-44251.
Crossref

Susanne R. Tepper, Zhixiang Zuo, Arun Khattri, Jochen Heß & Tanguy Y. Seiwert. (2016) Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas. Oral Oncology 56, pages 62-70.
Crossref

Hua Li, Sarah Wheeler, Yongseok Park, Zhenlin Ju, Sufi M. Thomas, Michele Fichera, Ann M. Egloff, Vivian W. Lui, Umamaheswar Duvvuri, Julie E. Bauman, Gordon B. Mills & Jennifer R. Grandis. (2016) Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts. Molecular Cancer Research 14:3, pages 278-286.
Crossref

Stefan W. Stoll, Philip E. Stuart, Sylviane Lambert, Alberto Gandarillas, Laure Rittié, Andrew Johnston & James T. Elder. (2016) Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation. Journal of Investigative Dermatology 136:2, pages 444-452.
Crossref

Blake M. Warner & Jennifer Grandis. 2016. Targeting Oral Cancer. Targeting Oral Cancer 163 209 .

E.Yu. Moskaleva, V.G. Perevozchikova, A.S. Zhirnik & S.E. Severin. (2015) Molecular mechanisms of niclosamide antitumor activity. Biomeditsinskaya Khimiya 61:6, pages 680-693.
Crossref

E. Yu. Moskaleva, V. G. Perevozchikova, A. S. Zhirnik & S. E. Severin. (2015) Molecular mechanisms of antitumor activity of niclosamide. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 9:4, pages 312-324.
Crossref

Julie E. Bauman & Jennifer R. Grandis. (2014) Targeting secondary immune responses to cetuximab: CD137 and the outside story. Journal of Clinical Investigation 124:6, pages 2371-2375.
Crossref

Patrick L. Garcia, Leona N. Council, John D. Christein, J. Pablo Arnoletti, Marty J. Heslin, Tracy L. Gamblin, Joseph H. Richardson, Mary-Ann Bjornsti & Karina J. Yoon. (2013) Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma. PLoS ONE 8:10, pages e78183.
Crossref

Rui Li, Shuo You, Zhongliang Hu, Zhuo G. Chen, Gabriel L. Sica, Fadlo R. Khuri, Walter J. Curran, Dong M. Shin & Xingming Deng. (2013) Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer. PLoS ONE 8:9, pages e74670.
Crossref

Laura P. Stabile, Guoqing He, Vivian Wai Yan Lui, Sufi M. Thomas, Cassandra Henry, Christopher T. Gubish, Sonali Joyce, Kelly M. Quesnelle, Jill M. Siegfried & Jennifer R. Grandis. (2013) c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research 19:2, pages 380-392.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer

Articles from other publishers (23)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer

Citations (23)

Articles from other publishers (23)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date